Endoscopy 2020; 52(03): 193-201
DOI: 10.1055/a-1024-3967
Original article
© Georg Thieme Verlag KG Stuttgart · New York

A novel cryoballoon ablation system for eradication of dysplastic Barrett’s esophagus: a first-in-human feasibility study

Sanne Noortje van Munster*
1   Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, the Netherlands
2   Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, the Netherlands
,
Anouk Overwater*
1   Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, the Netherlands
3   Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht University, the Netherlands
,
Mihaela G. M. Raicu
4   Pathology DNA, St. Antonius Hospital, Nieuwegein, the Netherlands
,
Kees C. A. Seldenrijk
4   Pathology DNA, St. Antonius Hospital, Nieuwegein, the Netherlands
,
Wouter B. Nagengast
5   Department of Gastroenterology and Hepatology, University Medical Center Groningen, the Netherlands
,
Erik J. Schoon
6   Department of Gastroenterology and Hepatology, Catharina Hospital Eindhoven, the Netherlands
,
Jacques J. G. H. M. Bergman
2   Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, the Netherlands
,
Bas L. A. M. Weusten
1   Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, the Netherlands
3   Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht University, the Netherlands
› Author Affiliations
Further Information

Publication History

submitted 27 May 2019

accepted after revision 10 September 2019

Publication Date:
11 November 2019 (online)

Abstract

Background Endoscopic cryoablation for Barrett’s esophagus (BE) might offer advantages over heat-based ablation. Focal cryoballoon ablation has been promising for short-segment BE, whereas the novel 90°-swipe cryoballoon ablation system (CbSAS90) ablates larger areas in a single step (90° over 3 cm). The system allows for dose adjustment. CbSAS90 has been feasible and safe in animal and pre-esophagectomy studies. This is the first clinical study to assess feasibility, safety, and efficacy of CbSAS90 for eradication of dysplastic BE.

Methods In this prospective study in dysplastic BE patients, dose finding started with semi-circumferential treatment at 0.8 mm/s (dose 1). The dose was escalated by reducing speed by 0.1 mm/s in six patients until BE surface regression was ≥ 80 % without complications (“effective dose”). The effective dose was subsequently confirmed with circumferential treatment in 12 new patients. Post-procedural pain (0 – 10) and dysphagia (0 – 4) were evaluated. Outcomes were feasibility, safety, and BE surface regression.

Results 25 patients were included, with technically successful treatment in 92 % (95 %CI 73 % – 99 %). Median (95 %CI) BE surface regression was 78 % (50 % – 85 %) for dose 1 and 85 % (55 % – 95 %) for dose 2 (0.7 mm/s), which was defined as the effective dose. Circumferential treatment resulted in 93 % (88 % – 96 %) regression. Two of 12 patients with circumferential treatment developed strictures that required dilation. Median pain and dysphagia scores were low (0 – 3 and 0, respectively).

Conclusions CbSAS90 was feasible and effective for ablating larger BE areas. The optimal dose for circumferential treatment that balances safety and efficacy requires further evaluation.

* These authors contributed equally to this work.


 
  • References

  • 1 Desai TK, Krishnan K, Samala N. et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut 2012; 61: 970-976
  • 2 Weusten B, Bisschops R, Coron E. et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017; 49: 191-198
  • 3 Baust JG, Gage AA. The molecular basis of cryosurgery. BJU Int 2005; 95: 1187-1191
  • 4 Spechler SJ, Sharma P. American Gastroenterological Association. et al. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology 2011; 140: 1084-1091
  • 5 Baust JG, Gage AA, Bjerklund Johansen TE. et al. Mechanisms of cryoablation: clinical consequences on malignant tumors. Cryobiology 2014; 68: 1-11
  • 6 van Munster SN, Overwater A, Haidry R. et al. Focal cryoballoon versus radiofrequency ablation of dysplastic Barrett’s esophagus: impact on treatment response and postprocedural pain. Gastrointest Endosc 2018; 88: 795-803.e2
  • 7 Solomon SS, Kothari S, Smallfield GB. et al. Liquid nitrogen spray cryotherapy is associated with less postprocedural pain than radiofrequency ablation in Barrett’s esophagus. J Clin Gastroenterol 2019; 53: e84-e90
  • 8 Overwater A, Weusten BLAM. Cryoablation in the management of Barrett’s esophagus. Curr Opin Gastroenterol 2017; 33: 261-269
  • 9 Johnston MH, Eastone JA, Horwhat JD. et al. Cryoablation of Barrett’s esophagus: a pilot study. Gastrointest Endosc 2005; 62: 842-848
  • 10 Xue H, Tan H, Liu W. et al. A pilot study of endoscopic spray cryotherapy by pressurized carbon dioxide gas for Barrett’s esophagus. Endoscopy 2011; 43: 379-385
  • 11 Schölvinck DW, Friedland S, Triadafilopoulos G. et al. Balloon-based esophageal cryoablation with a novel focal ablation device: dose-finding and safety in porcine and human models. Dis Esophagus 2017; 30: 1-8
  • 12 Canto MI, Shaheen NJ, Almario JA. et al. Multifocal nitrous oxide cryoballoon ablation with or without EMR for treatment of neoplastic Barrett’s esophagus (with video). Gastrointest Endosc 2018; 88: 438-446.e2
  • 13 Künzli H, Schölvinck D, Meijer S. et al. Efficacy of the CryoBalloon Focal Ablation System for the eradication of dysplastic Barrett’s esophagus islands. Endoscopy 2016; 49: 169-175
  • 14 Schölvinck D, Künzli H, Kestens C. et al. Treatment of Barrett’s esophagus with a novel focal cryoablation device: a safety and feasibility study. Endoscopy 2015; 47: 1106-1112
  • 15 Louie BE, Hofstetter W, Triadafilopoulos G. et al. Evaluation of a novel cryoballoon swipe ablation system in bench, porcine, and human esophagus models. Dis esophagus 2018; DOI: 10.1093/dote/dox155.
  • 16 Swager A-F, Curvers WL, Bergman JJ. Diagnosis by endoscopy and advanced imaging of Barrett’s neoplasia. In: Jansen M, Wright NA. , eds. Stem cells, pre-neoplasia, and early cancer of the upper gastrointestinal tract. Cham: Springer; 2016: 81-98
  • 17 Dische S, Saunders M, Barrett A. et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997; 44: 123-136
  • 18 Nederlandse Vereniging van Maag-darm-leverartsen. Richtlijn Barrett-Oesofagus. 2018 Available from: https://www.mdl.nl/sites/www.mdl.nl/files/richlijnen/Richtlijnen%20Barrett%20oesofagus%20-%20jan%202018%20-%20tbv%20website.pdf Accessed: 15 April 2019
  • 19 Pouw RE, Seewald S, Gondrie JJ. et al. Stepwise radical endoscopic resection for eradication of Barrett’s oesophagus with early neoplasia in a cohort of 169 patients. Gut 2010; 59: 1169-1177
  • 20 Trindade A, Canto M. Circumferential treatment of long-segment Barrett’s esophagus using the next-generation cryoballoon. Endoscopy 2019; 51: E69-E70
  • 21 Belghazi K, Pouw RE, Koch AD. et al. Self-sizing radiofrequency ablation balloon for eradication of Barrett’s esophagus: results of an international multicenter randomized trial comparing 3 different treatment regimens. Gastrointest Endosc 2019; 90: 415-423
  • 22 Zemlyak AY, Pacicco T, Mahmud EM. et al. Radiofrequency ablation offers a reliable surgical modality for the treatment of Barrett’s esophagus with a minimal learning curve. Am Surg 2012; 78: 774-778
  • 23 Peerally MF, Bhandari P, Ragunath K. et al. Radiofrequency ablation compared with argon plasma coagulation after endoscopic resection of high-grade dysplasia or stage T1 adenocarcinoma in Barrett’s esophagus: a randomized pilot study (BRIDE). Gastrointest Endosc 2019; 89: 680-689
  • 24 Shaheen NJ, Sharma P, Overholt BF. et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009; 360: 2277-2288
  • 25 van Vilsteren FGI, Alvarez Herrero L, Pouw RE. et al. Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett’s esophagus with early neoplasia: a prospective multicenter study. Endoscopy 2013; 45: 516-525
  • 26 Belghazi K, Pouw R, Sondermeijer C. et al. A single-step sizing and radiofrequency ablation catheter for circumferential ablation of Barrett’s esophagus: Results of a pilot study. United Eur Gastroenterol J 2018; 6: 990-999
  • 27 van Vilsteren FGI, Phoa KN, Alvarez Herrero L. et al. Circumferential balloon-based radiofrequency ablation of Barrett’s esophagus with dysplasia can be simplified, yet efficacy maintained, by omitting the cleaning phase. Clin Gastroenterol Hepatol 2013; 11: 491-498.e1
  • 28 Chadwick G, Groene O, Markar SR. et al. Systematic review comparing radiofrequency ablation and complete endoscopic resection in treating dysplastic Barrett’s esophagus: a critical assessment of histologic outcomes and adverse events. Gastrointest Endosc 2014; 79: 718-731.e3
  • 29 Pouw RE, Wirths K, Eisendrath P. et al. Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett’s esophagus with early neoplasia. Clin Gastroenterol Hepatol 2010; 8: 23-29
  • 30 Sharma VK, Jae Kim H, Das A. et al. Circumferential and focal ablation of Barrett’s esophagus containing dysplasia. Am J Gastroenterol 2009; 104: 310-317